Why the study?
Does myocardial viral persistence impact the risk of death or heart transplantation in patients with dilated cardiomyopathy?
Does myocardial viral persistence impact the risk of death or heart transplantation in patients with dilated cardiomyopathy?
The presence of viral genomes in the myocardium of patients with stable dilated cardiomyopathy does not appear to significantly impact long-term clinical outcomes such as death or heart transplantation.
No takes yet. Share an insight, caveat, or question.
Should not prompt changes in dilated cardiomyopathy management based on viral genome status; leaves open the need for larger prospective studies.
Nowalany-Kozielska et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: